METHOD AND COMPOSITION FOR PREDICTING LONG-TERM SURVIVAL IN CANCER IMMUNOTHERAPY

• Main Author: KAGAMU HIROSHI
• Format: Patent
• Language: Chinese; English
• Published: 26.11.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

Provided is a peripheral blood biomarker for predicting the long-term survival/need for therapeutic intervention in cancer immunotherapy. The present invention provides a method that uses a composition of a cell subpopulation in a sample obtained from a subject as an indicator to predict the long-term survival of the subject in cancer immunotherapy. The long-term survival/need for therapeutic intervention in a subject in cancer immunotherapy can be predicted by comparing the level of a CD4+ T cell subpopulation that correlates with dendritic cell stimulation in an antitumor immune response or a dendritic cell subpopulation that correlates with dendritic cell stimulation in an antitumor immune response with a reference standard. 提供用于预测癌症免疫疗法中的长期存活/治疗干预的必要性的外周血生物标志物。本发明提供一种方法，其将从受试者获得的样品中的细胞亚群的组成用作受试者在癌症免疫疗法中的长期存活预测的指标。通过将与抗肿瘤免疫应答中的树突状细胞刺激相关的CD4+T细胞亚群的量、或与抗肿瘤免疫应答中的树突状细胞刺激相关的树突状细胞亚群的量与基准进行比较，能够预测受试者在癌症免疫疗法中的长期存活/治疗干预的必要性。